Rapid Micro Biosystems stock fell 3.46 percent as losses persisted

Published on 10/07/2026 at 06:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rapid Micro Biosystems stock carries a USD 5.75 consensus target from four analysts as of October 6, 2026. Q2 revenue reached USD 8.05 million, up 11 percent year over year.

RPID, US75340L1044, Illustration mit AI erstellt.

Rapid Micro Biosystems stock (ISIN US75340L1044) fell 3.46 percent to USD 0.94 on Nasdaq on October 6, 2026 at 4:00 p.m. ET. The move leaves the company valued at USD 42.7 million, while its second-quarter results show revenue growth alongside a persistent loss.

Revenue reached USD 8.05 million

Rapid Micro Biosystems reported second-quarter 2026 revenue of USD 8.054 million for the period ended June 30, 2026. Revenue increased 11 percent from the second quarter of 2025, giving the company a measurable top-line gain despite the share-price decline.

The quarter also brought a gross margin of 15 percent, an 11 percentage-point improvement from the prior-year quarter. Cash and cash equivalents stood at USD 14.687 million at June 30, 2026, while operating cash flow was negative USD 12.702 million for the quarter.

Loss remains the central risk

Rapid Micro Biosystems posted a consolidated net loss of USD 12.923 million in Q2 2026, equal to diluted EPS of negative USD 0.27. The loss was narrower than the USD 14.275 million recorded in Q1 2026, but the negative result keeps profitability as the key operating test for the business.

The company develops the Growth Direct platform for automated microbial quality control in pharmaceutical manufacturing. Its investor-relations page describes applications across biologics, vaccines, cell and gene therapies, and sterile injectables, linking the investment case to adoption of laboratory automation rather than to a single product launch.

Analysts see a wide valuation gap

According to Investing.com, the analyst consensus as of October 6, 2026 is Strong Buy from four analysts. The average 12-month target is USD 5.75, with a USD 3.00 low and USD 8.00 high, placing the average target 511.7 percent above the USD 0.94 Nasdaq price.

Separately, Investing.com reported on September 29, 2026 that Roth/MKM initiated coverage with a Buy rating and a USD 3.00 price target. The target is 219.1 percent above the October 6 price, but the gap also reflects the companys continuing losses and the execution required to convert system placements into recurring revenue.

RPID trades near its yearly floor

Rapid Micro Biosystems was last at USD 0.94 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, with 162,258 shares traded. Its 52-week range was USD 0.86 to USD 4.94, leaving the stock 9.3 percent above the low and 81.0 percent below the high.